Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bayer received approval in Japan for Nexavar tablets for the treatment of unresectable hepatocellular carcinoma from the Ministry of Health, Labour and Welfare. Nexavar, an oral anti-cancer drug, jointly developed by Bayer HealthCare AG and Onyx Pharmaceuticals, Inc., is the only drug therapy shown to significantly improve overall survival in patients with the disease. The product is already marketed in Japan as a therapy for unresectable or metastatic renal cell carcinoma.

Today in Drug/Product Alerts...keeping you current

Generic drugs dominate market, look to expand into biologics
Formulary , 12/16/09

Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09

Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address